MAR 11, 2018 9:39 PM PDT

New Drug for Multiple Sclerosis? Potential Therapeutic Treatment Uncovered

WRITTEN BY: Nouran Amin

Multiple sclerosis (MS) is a neurological disease that is unpredictable and often disabling in affected individuals. It is more specifically a disease of the central nervous system (CNS) that afflicts the transport of information in the brain, and how this information is being transmitted to the rest of the body.

 

Unfortunately, there is currently no cure for MS; however, recent research at Mainz University Medical Center in collaboration with the University of Montreal has proposed a new treatment. The researchers experimented in model mice using endothelial cells and discovered that a protein known as EGFL7 hinders the transportation of immune cells into the CNS by maintaining the blood-brain barrier.

The research team leaders are Dr. Timo Uphaus and Professor Frauke Zipp of the Department of Neurology at the University Medical Center of Johannes Gutenberg University Mainz in collaboration with Dr. Catherine Larochelle of the University of Montreal and Professor Mirko Schmidt as well as researchers of the German Cancer Consortium (DKTK). The purpose of the research study is to develop a drug treatment that will stop the pathology of MS from progressing. The focus was the molecule EGFL7 and its role in cell migration MS.

EGFL7 is released into the blood-brain barrier by endothelial cells. In breast cancer, EGFL7 was examined not to have an influence on cellular migration to tumor tissue. For MS, the significance of immune cells is its migration to the brain; this motivated researchers to investigate the relationship between cell migration and the protein EGFL7, and later to propose a treatment for MS.

Investigators discovered that inflammation in the central nervous system was due to increased levels of EGFL7. Since immune cells bind to EGFL7, the protein cannot cross into the central nervous system. When EGFL7 is released, the immune cells are retained in the perivascular space. In model trials, the investigators found that exposure to the protein made the blood-brain barrier less permeable. Additionally, the transportation of immune cells into the central nervous system was reduced.

These discoveries opposed the pathological characteristics of MS and improved the clinical symptoms. The findings concluded that in a human blood-brain barrier model, the migration of immune cells was greatly reduced in isolated endothelial cells. Researchers believe that it may be possible to use EGFL7’s inhibiting properties on migrating immune cells as well as the proteins ability to enhance the impenetrability of the blood-brain barrier. Overall, the results illustrate how EGFL7 can limit CNS immune cell invasion encouraging a potential drug development that involves EGFL7 agonist in the treatment of MS.

The research study was published in Nature Communications.

Sources: Nature Communications, Drug Target Review, National MS Society

 

 

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 15, 2021
Drug Discovery & Development
Magic Mushroom Therapy and Antidepressants Produce Similar Results
APR 15, 2021
Magic Mushroom Therapy and Antidepressants Produce Similar Results
In recent years, psilocybin (the psychoactive ingredient in 'magic mushrooms') has gained increasing amounts of ...
MAY 15, 2021
Drug Discovery & Development
New Drug Blocks Critical Step in Malaria Life Cycle
MAY 15, 2021
New Drug Blocks Critical Step in Malaria Life Cycle
According to the World Health Organization (WHO), in 2019, there were approximately 229 million cases of malaria around ...
MAY 19, 2021
Drug Discovery & Development
Combination Immunotherapy Shows Promise in Treating HIV
MAY 19, 2021
Combination Immunotherapy Shows Promise in Treating HIV
  Researchers have found that a new combination immunotherapy, alongside antiretroviral therapy (ART), is effective ...
JUN 03, 2021
Drug Discovery & Development
Antibiotics Ineffective Against Lung-Scarring Disease
JUN 03, 2021
Antibiotics Ineffective Against Lung-Scarring Disease
Researchers behind a large trial of antibiotics for chronic lung diseases have found that that the drugs are ineffective ...
JUL 15, 2021
Drug Discovery & Development
The genomics of high blood pressure - a road to the future of treatment
JUL 15, 2021
The genomics of high blood pressure - a road to the future of treatment
The human heart begins to beat in utero in the early weeks of development and continues throughout life. In an average l ...
JUL 22, 2021
Drug Discovery & Development
Enhancing Myelin to Treat Alzheimer's Disease
JUL 22, 2021
Enhancing Myelin to Treat Alzheimer's Disease
Brain cells, or neurons, communicate through electrochemical signals. The electrical signals travel down a neuron’ ...
Loading Comments...